Every Form 4 that Eloxx Pharmaceut (ELOX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ELOX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELOX filings page.
Eloxx Pharmaceuticals, Inc. reported that 10% owner Domicilium Real Estate Fund III LP, through affiliated investment entities, restructured its position in pre-funded warrants and common stock. Several transactions coded "J" as "other acquisition or disposition" reflect exchanges of Pre-Funded Warrants into common shares pursuant to their terms.
Footnotes state that each Pre-Funded Warrant was exchanged for one share of Eloxx common stock and that the warrants have no expiration date and are exercisable at any time, subject to a 19.99% beneficial ownership cap. All holdings are reported as indirect, through funds and LLCs advised by Domicilium and managed by Daniel Simon. No open-market purchases or sales are reported in this filing.
Eloxx Pharmaceuticals director Stephen W. Webster received a new stock option grant. On the reported date, he was awarded options to acquire 13,587 shares of Eloxx common stock at an exercise price of $11.00 per share. These options vest in 24 substantially equal monthly installments and will be fully vested on the second anniversary of the grant date, as long as he continues serving the company. Following this grant, Webster holds 13,587 stock options directly under this award, which are scheduled to expire on June 8, 2036.
Eloxx Pharmaceuticals director Alan Edmund Walts received a grant of 8,590 stock options to buy common stock. The options have an exercise price of $11.00 per share and expire on June 8, 2036. They vest in 24 substantially equal monthly installments, becoming fully exercisable on the second anniversary of the grant date, as long as he continues to serve the company. Following this award, he holds 8,590 stock options directly, and the filing does not show any open-market purchases or sales.
Eloxx Pharmaceuticals director Nina S. Kjellson received a grant of stock options covering 13,587 shares of Common Stock. The options have an exercise price of $11.00 per share and expire on June 8, 2036. They vest in 24 substantially equal monthly installments over two years, conditioned on her continued service. Following this grant, she holds 13,587 stock options directly, reflecting a compensation-related award rather than an open-market purchase or sale.
Eloxx Pharmaceuticals, Inc. reported that President and CEO Sumit Aggarwal received a grant of stock options covering 328,833 shares of common stock. These options have an exercise price of $1.65 per share and expire on September 19, 2035.
The options were originally granted on September 19, 2025 and were subject to a performance-based vesting condition that was satisfied on June 10, 2026. Vesting will occur as to 1/36 of the options on July 31, 2026, with the remaining options vesting in equal monthly installments over the following 35 months, contingent on Aggarwal’s continued service.
Eloxx Pharmaceuticals director Steven D. Rubin received a new stock option grant. The award covers 4,018 options to buy Eloxx common stock at an exercise price of $11.00 per share and expires on June 8, 2036.
The option vests in 24 substantially equal monthly installments, becoming fully vested on the second anniversary of the June 8, 2026 grant date, as long as Rubin continues to provide service to the company. After this grant, he holds 4,018 stock options directly.
Domicilium Real Estate Fund III LP, a ten percent owner of Eloxx Pharmaceuticals, Inc., reported a restructuring of its position rather than an open-market trade. According to the filing, the Fund exchanged 1,250,000 shares of Eloxx common stock for pre-funded warrants to purchase an equivalent number of common shares.
Footnotes explain that all share amounts reflect an 11-for-1 reverse stock split effective May 29, 2026. After this adjustment, the Fund reports holding 238,422 pre-funded warrants directly and 14,285 shares of common stock indirectly through related entities. The pre-funded warrants have a $0.0000 exercise price, no expiration date, and include a 4.99% cap that prevents exercises if the holder would beneficially own more than 4.99% of outstanding common shares immediately after exercise.
Coastlands Capital LP, a ten percent owner of Eloxx Pharmaceuticals, Inc., reported an internal restructuring of its position. On May 27, 2026, it exchanged 1,250,000 shares of common stock for pre-funded warrants to purchase an equivalent number of common shares at an exercise price of $0.01 per share. Following the transaction, Coastlands held no common stock indirectly through Coastlands Capital LP and instead reported 30,612,243 pre-funded warrants. These pre-funded warrants are exercisable at any time, have no expiration date, and are subject to a 4.99% beneficial ownership limitation, which restricts exercises that would push holdings above that level.
Eloxx Pharmaceuticals director Steven D. Rubin reported routine equity compensation activity. On January 24, 2026, he exercised 1,875 restricted stock units (RSUs), receiving an equal number of common shares at $0.00 per share, lifting his direct common stock holdings to 14,625 shares.
Following this RSU conversion, Rubin still held 1,875 RSUs. Earlier, on September 19, 2025, he received a grant of 179,854 stock options for common stock at a $0.15 exercise price, vesting 1/36 on October 31, 2025, then in equal monthly installments over 35 months until September 2035.
Eloxx Pharmaceuticals’ President and CEO Sumit Aggarwal reported a series of compensation-related equity moves. On February 28, 2026, he exercised options to acquire 260,946 shares of common stock at $0.15 per share, bringing his directly held common stock to 1,672,756 shares.
Earlier, on January 24, 2026, 15,000 restricted stock units converted into an equal number of common shares. On September 19, 2025, he received an award of 1,000,000 common shares and 3,597,090 stock options with a $0.15 exercise price expiring in 2035. On August 14, 2025, he exercised options to acquire 196,880 shares at an exercise price of $0.0001 per share.
Footnotes state that several older options granted in 2021–2023 were cancelled and replaced with new options at lower exercise prices, and that the board accelerated vesting or waived performance conditions in connection with certain exercises and grants.
Eloxx Pharmaceuticals director Alan Edmund Walts reported equity compensation activity, not open‑market trading. On January 24, 2026, he exercised 1,875 restricted stock units, receiving an equal number of common shares at a stated price of $0.00 per share, bringing his directly held common stock to 15,567 shares.
A prior grant on September 19, 2025 awarded him a stock option for 395,680 shares of common stock at an exercise price of $0.15 per share, expiring on September 19, 2035. The option vests over 36 months, and the RSUs vested 50% after one year with the balance in two annual installments.